FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
2 reports, 2 independent
Updated Sep 23
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA grants accelerated approval to INO-3107 following mid-cycle review.1 source
Inovio received mid-cycle review from the FDA for INO-3107 and appointed EY as its accounting firm.1 source
Keep exploring
The entities involved
- FDA
-
Inovio Pharmaceuticals
American biotechnology company
Nothing else this week.
-
Ernst & Young LLP
Nothing else this week.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.
- Unicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.
- enVVeno Medical received IDE approval from the FDA for its pivotal study on July 31, 2026.